CRNX

+ Watchlist + Portfolio

Crinetics Pharmaceuticals, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $84.69
52-Week Range: $28.73 – $84.80
Market Cap: $8.99B
P/E (TTM): —
EPS (TTM): -5.05
Dividend Yield: —

Advanced Metrics

Price/Book: 7.52
PEG Ratio: —
Return on Equity: -42.45%
Return on Assets: -26.28%
Gross Margin: 0.00%
Operating Margin: -527.35%
Profit Margin: 0.00%
Current Ratio: 15.57
Debt/Equity: 0.04
Total Debt: $47.19M
Free Cash Flow: $-248.76M
Revenue Growth: 2336.30%
Earnings Growth: —
Enterprise Value: $7.82B

CRNX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$4.74M	$4.01M	$1.04M	$7.70M
Cost of Revenue	—	$0.00	$0.00	$1.08M
Gross Profit	—	$4.01M	$1.04M	$6.62M
Research & Development	$130.22M	$168.53M	$240.16M	$332.06M
Selling, General & Admin	$42.39M	$58.09M	$99.74M	$191.33M
Operating Expenses	$172.62M	$226.62M	$339.89M	$523.39M
Operating Income	-$167.88M	-$222.61M	-$338.85M	-$516.77M
EBITDA	-$166.90M	-$221.51M	-$336.07M	-$512.88M
Pretax Income	-$163.92M	-$214.53M	-$298.41M	-$465.14M
Income Tax	—	$0.00	$0.00	$180.00K
Net Income	-$163.92M	-$214.53M	-$298.41M	-$465.32M
Diluted EPS	-3.15	-3.69	-3.69	-4.95
Diluted Shares	51.98M	58.07M	80.78M	94.06M

CRNX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$32.67M	$54.90M	$264.55M	$101.54M
Receivables	$3.03M	$9.35M	$0.00	$592.00K
Inventory	—	—	$0.00	$2.02M
Current Assets	$345.18M	$574.15M	$1.38B	$1.05B
Total Assets	$352.18M	$635.35M	$1.43B	$1.13B
Current Liabilities	$27.72M	$43.94M	$59.68M	$85.07M
Total Debt	$3.08M	$51.73M	$51.72M	$48.54M
Total Liabilities	$35.85M	$96.25M	$109.79M	$134.17M
Retained Earnings	-$439.17M	-$653.70M	-$952.11M	-$1.42B
Shareholders' Equity	$316.33M	$539.11M	$1.32B	$992.08M
Working Capital	$317.46M	$530.21M	$1.32B	$963.27M

CRNX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$115.20M	-$168.60M	-$230.19M	-$377.92M
Capital Expenditure	-$1.66M	-$4.69M	-$3.84M	-$5.76M
Free Cash Flow	-$116.86M	-$173.29M	-$234.04M	-$383.68M
Depreciation & Amortisation	$983.00K	$1.10M	$2.79M	$3.89M
Stock-Based Compensation	$28.27M	$40.94M	$69.39M	$91.02M
Investing Cash Flow	-$173.98M	-$200.41M	-$574.82M	$173.91M
Financing Cash Flow	$121.96M	$391.24M	$1.01B	$40.61M
Share Repurchases	—	-$541.00K	-$14.98M	$0.00
Net Change in Cash	-$167.22M	$22.22M	$209.65M	-$163.40M

CRNX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$361.00K	$1.03M	$143.00K	$6.16M	$10.73M
Cost of Revenue	$0.00	—	—	—	$200.00K
Gross Profit	$361.00K	—	—	—	$10.53M
Research & Development	$76.24M	$80.30M	$90.46M	$85.05M	$100.08M
Selling, General & Admin	$35.53M	$49.84M	$52.27M	$53.70M	$50.83M
Operating Expenses	$111.77M	$130.14M	$142.73M	$138.75M	$150.91M
Operating Income	-$111.41M	-$129.11M	-$142.59M	-$133.67M	-$140.38M
EBITDA	-$110.48M	-$128.15M	-$141.57M	-$132.67M	-$139.22M
Pretax Income	-$96.77M	-$115.64M	-$130.09M	-$122.64M	-$127.84M
Net Income	-$96.77M	-$115.64M	-$130.09M	-$122.81M	-$127.84M
Diluted EPS	-1.04	-1.23	-1.38	-1.29	-1.23
Diluted Shares	93.10M	93.79M	94.22M	95.10M	104.10M

CRNX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$94.57M	$53.73M	$110.90M	$101.54M	$114.34M
Receivables	$7.31M	—	—	$592.00K	$5.68M
Inventory	—	—	—	$2.02M	$3.06M
Current Assets	$1.29B	$1.22B	$1.12B	$1.05B	$1.32B
Total Assets	$1.36B	$1.29B	$1.20B	$1.13B	$1.40B
Current Liabilities	$57.31M	$68.40M	$74.16M	$85.07M	$71.09M
Total Debt	$50.82M	$49.94M	$49.14M	$48.54M	$47.85M
Total Liabilities	$107.33M	$118.05M	$123.86M	$134.17M	$120.68M
Retained Earnings	-$1.05B	-$1.16B	-$1.29B	-$1.42B	-$1.55B
Shareholders' Equity	$1.25B	$1.17B	$1.07B	$992.08M	$1.28B
Working Capital	$1.23B	$1.15B	$1.05B	$963.27M	$1.25B

CRNX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$88.45M	-$85.85M	-$110.72M	-$92.90M	-$124.70M
Capital Expenditure	-$1.24M	-$3.20M	-$863.00K	-$458.00K	-$820.00K
Free Cash Flow	-$89.69M	-$89.05M	-$111.58M	-$93.36M	-$125.52M
Depreciation & Amortisation	$925.00K	$959.00K	$1.01M	$994.00K	$1.16M
Stock-Based Compensation	$20.48M	$26.12M	$22.70M	$21.72M	$29.68M
Investing Cash Flow	-$85.96M	$37.95M	$164.81M	$57.11M	-$252.36M
Financing Cash Flow	$4.44M	$7.05M	$3.08M	$26.04M	$389.88M
Share Repurchases	$0.00	—	—	—	-$578.00K
Net Change in Cash	-$169.98M	-$40.84M	$57.17M	-$9.76M	$12.81M

Market Snapshot

About

Crinetics Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for endocrine diseases and endocrine-related tumors. Headquartered in San Diego, California, the company is advancing a pipeline of small molecule therapeutics targeting rare and common endocrine disorders. Crinetics' lead product candidate, paltusotine, is being developed for acromegaly and carcinoid syndrome. The company's proprietary drug discovery platform focuses on G protein-coupled receptors (GPCRs).